Gregg W Stone, Harry P Selker, Holger Thiele, Manesh R Patel, James E Udelson, E Magnus Ohman, Akiko Maehara, Ingo Eitel, Christopher B Granger, Paul L Jenkins, Melissa Nichols, Ori Ben-Yehuda
Index: J. Am. Coll. Cardiol. 67 , 1674-83, (2016)
Full Text: HTML
Prompt reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) reduces infarct size and improves survival. However, the intuitive link between infarct size and prognosis has not been convincingly demonstrated in the contemporary era.This study sought to determine the strength of the relationship between infarct size assessed early after primary percutaneous coronary intervention (PCI) in STEMI and subsequent all-cause mortality, reinfarction, and hospitalization for heart failure.We performed a pooled patient-level analysis from 10 randomized primary PCI trials (total 2,632 patients) in which infarct size was assessed within 1 month after randomization by either cardiac magnetic resonance (CMR) imaging or technetium-99m sestamibi single-photon emission computed tomography (SPECT), with clinical follow-up for ≥ 6 months.Infarct size was assessed by CMR in 1,889 patients (71.8%) and by SPECT in 743 patients (28.2%). Median (25th, 75th percentile) time to infarct size measurement was 4 days (3, 10 days) after STEMI. Median infarct size (% left ventricular myocardial mass) was 17.9% (8.0%, 29.8%), and median duration of clinical follow-up was 352 days (185, 371 days). The Kaplan-Meier estimated 1-year rates of all-cause mortality, reinfarction, and HF hospitalization were 2.2%, 2.5%, and 2.6%, respectively. A strong graded response was present between infarct size (per 5% increase) and subsequent mortality (Cox-adjusted hazard ratio: 1.19 [95% confidence interval: 1.18 to 1.20]; p < 0.0001) and hospitalization for heart failure (adjusted hazard ratio: 1.20 [95% confidence interval: 1.19 to 1.21]; p < 0.0001), independent of age, sex, diabetes, hypertension, hyperlipidemia, current smoking, left anterior descending versus non-left anterior descending infarct vessel, symptom-to-first device time, and baseline TIMI (Thrombolysis In Myocardial Infarction) flow 0/1 versus 2/3. Infarct size was not significantly related to subsequent reinfarction.Infarct size, measured by CMR or technetium-99m sestamibi SPECT within 1 month after primary PCI, is strongly associated with all-cause mortality and hospitalization for HF within 1 year. Infarct size may, therefore, be useful as an endpoint in clinical trials and as an important prognostic measure when caring for patients with STEMI.Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
AIDA
CAS:168560-79-0 |
C11H11NO4 |
Bordetella pertussis Adenylate Cyclase Toxin Blocks Inductio...
2015-05-15 [J. Immunol. 194 , 4901-13, (2015)] |
Cross talk between ABC transporter mRNAs via a target mRNA-d...
2015-06-03 [EMBO J. 34 , 1478-92, (2015)] |
In vivo evaluation of porous silicon and porous silicon soli...
2014-08-04 [Mol. Pharm. 11(8) , 2876-86, (2014)] |
Extrasynaptic glutamate release through cystine/glutamate an...
2014-08-01 [J. Clin. Invest. 124(8) , 3645-55, (2014)] |
mGluR5 protect astrocytes from ischemic damage in postnatal ...
2015-11-01 [Cell Calcium 58 , 423-30, (2015)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved